BioLife Solns Analyst Ratings
BioLife Solns Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/09/2023 | 76.93% | Lake Street | $34 → $25 | Maintains | Buy |
| 07/17/2023 | 105.24% | Stephens & Co. | $27 → $29 | Maintains | Overweight |
| 07/11/2023 | 105.24% | Craig-Hallum | → $29 | Initiates Coverage On | → Buy |
| 03/17/2023 | 91.08% | Stephens & Co. | $31 → $27 | Maintains | Overweight |
| 03/06/2023 | 98.16% | Oppenheimer | → $28 | Reiterates | → Outperform |
| 05/10/2022 | 183.09% | Stephens & Co. | $47 → $40 | Maintains | Overweight |
| 05/10/2022 | 112.31% | Keybanc | $60 → $30 | Maintains | Overweight |
| 04/25/2022 | 98.16% | Oppenheimer | → $28 | Upgrades | Perform → Outperform |
| 08/13/2021 | 324.63% | Keybanc | $50 → $60 | Maintains | Overweight |
| 05/14/2021 | — | Benchmark | Downgrades | Buy → Hold | |
| 03/23/2021 | 282.17% | Benchmark | → $54 | Upgrades | Hold → Buy |
| 03/23/2021 | 253.86% | Keybanc | $40 → $50 | Maintains | Overweight |
| 11/10/2020 | 183.09% | Keybanc | → $40 | Initiates Coverage On | → Overweight |
| 09/22/2020 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 09/18/2020 | 133.55% | Cowen & Co. | → $33 | Initiates Coverage On | → Outperform |
| 08/11/2020 | — | Benchmark | Downgrades | Buy → Hold | |
| 05/04/2020 | 55.7% | B. Riley Securities | $24 → $22 | Maintains | Buy |
| 03/23/2020 | 20.31% | HC Wainwright & Co. | $26 → $17 | Maintains | Buy |
| 03/12/2020 | 69.85% | B. Riley Securities | $27 → $24 | Maintains | Buy |
| 02/24/2020 | 76.93% | Lake Street | → $25 | Initiates Coverage On | → Buy |
| 02/19/2020 | 69.85% | Benchmark | → $24 | Initiates Coverage On | → Buy |
| 02/06/2020 | 91.08% | B. Riley Securities | → $27 | Initiates Coverage On | → Buy |
| 12/16/2019 | 84.01% | HC Wainwright & Co. | $23 → $26 | Reiterates | → Buy |
| 11/21/2019 | 55.7% | Oppenheimer | → $22 | Initiates Coverage On | → Outperform |
| 09/04/2019 | 55.7% | Northland Capital Markets | $18 → $22 | Maintains | Outperform |
| 07/22/2019 | 62.77% | HC Wainwright & Co. | → $23 | Initiates Coverage On | → Buy |
| 10/03/2018 | 55.7% | B. Riley Securities | $23 → $22 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 08/09/2023 | 76.93% | 莱克街 | $34→$25 | 维护 | 买 |
| 07/17/2023 | 105.24% | 斯蒂芬斯公司 | $27→$29 | 维护 | 超重 |
| 07/11/2023 | 105.24% | 克雷格-哈勒姆 | →$29 | 开始承保 | →购买 |
| 03/17/2023 | 91.08% | 斯蒂芬斯公司 | $31→$27 | 维护 | 超重 |
| 03/06/2023 | 98.16% | 奥本海默 | →$28 | 重申 | →跑赢大盘 |
| 2022年05月10日 | 183.09% | 斯蒂芬斯公司 | $47→$40 | 维护 | 超重 |
| 2022年05月10日 | 112.31% | KeyBanc | $60→$30 | 维护 | 超重 |
| 04/25/2022 | 98.16% | 奥本海默 | →$28 | 升级 | →表现强于大盘 |
| 2021/08/13 | 324.63% | KeyBanc | $50→$60 | 维护 | 超重 |
| 2021/05/14 | - | 基准 | 评级下调 | 购买→Hold | |
| 03/23/2021 | 282.17% | 基准 | →$54 | 升级 | 持有→购买 |
| 03/23/2021 | 253.86% | KeyBanc | $40→$50 | 维护 | 超重 |
| 11/10/2020 | 183.09% | KeyBanc | →$40 | 开始承保 | →超重 |
| 09/22/2020 | - | 奥本海默 | 评级下调 | 超越→表现 | |
| 09/18/2020 | 133.55% | 考恩公司 | →$33 | 开始承保 | →跑赢大盘 |
| 2020年08月11日 | - | 基准 | 评级下调 | 购买→Hold | |
| 05/04/2020 | 55.7% | B.莱利证券 | $24→$22 | 维护 | 买 |
| 03/23/2020 | 20.31% | HC Wainwright公司 | $26→$17 | 维护 | 买 |
| 03/12/2020 | 69.85% | B.莱利证券 | $27→$24 | 维护 | 买 |
| 02/24/2020 | 76.93% | 莱克街 | →$25 | 开始承保 | →购买 |
| 02/19/2020 | 69.85% | 基准 | →$24 | 开始承保 | →购买 |
| 02/06/2020 | 91.08% | B.莱利证券 | →$27 | 开始承保 | →购买 |
| 2019年12月16日 | 84.01% | HC Wainwright公司 | $23→$26 | 重申 | →购买 |
| 2019年11月21日 | 55.7% | 奥本海默 | →$22 | 开始承保 | →跑赢大盘 |
| 2019年09月04日 | 55.7% | 北国资本市场 | $18→$22 | 维护 | 跑赢大盘 |
| 2019年07月22日 | 62.77% | HC Wainwright公司 | →$23 | 开始承保 | →购买 |
| 10/03/2018 | 55.7% | B.莱利证券 | $23→$22 | 维护 | 买 |
What is the target price for BioLife Solns (BLFS)?
BioLife Solns(BLFS)的目标价格是多少？
The latest price target for BioLife Solns (NASDAQ: BLFS) was reported by Lake Street on August 9, 2023. The analyst firm set a price target for $25.00 expecting BLFS to rise to within 12 months (a possible 76.93% upside). 5 analyst firms have reported ratings in the last year.
Lake Street于2023年8月9日报道了BioLife Solns(纳斯达克：BLFS)的最新目标价。这家分析公司将目标价定为25.00美元，预计BLFS将在12个月内升至(可能上涨76.93%)。去年有5家分析公司公布了评级。
What is the most recent analyst rating for BioLife Solns (BLFS)?
BioLife Solns(BLFS)的最新分析师评级是多少？
The latest analyst rating for BioLife Solns (NASDAQ: BLFS) was provided by Lake Street, and BioLife Solns maintained their buy rating.
Lake Street提供了对BioLife Solns(纳斯达克代码：BLFS)的最新分析师评级，BioLife Solns维持买入评级。
When is the next analyst rating going to be posted or updated for BioLife Solns (BLFS)?
BioLife Solns(BLFS)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioLife Solns, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioLife Solns was filed on August 9, 2023 so you should expect the next rating to be made available sometime around August 9, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与BioLife Solns的高管和客户交谈，以及收听收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。BioLife Solns的上一次评级是在2023年8月9日提交的，所以你应该预计下一次评级将在2024年8月9日左右提供。
Is the Analyst Rating BioLife Solns (BLFS) correct?
分析师对BioLife Solns(BLFS)的评级正确吗？
While ratings are subjective and will change, the latest BioLife Solns (BLFS) rating was a maintained with a price target of $34.00 to $25.00. The current price BioLife Solns (BLFS) is trading at is $14.13, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的BioLife Solns(BLFS)评级维持不变，目标价在34.00美元至25.00美元之间。BioLife Solns目前的股价为14.13美元，超出了分析师的预期区间。